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More than 100,000 genetic variants are classified as disease causing in public databases. However, the true penetrance of many of these
rare alleles is uncertain and might be over-estimated by clinical ascertainment. Here, we use data from 379,768 UK Biobank (UKB) par-
ticipants of European ancestry to assess the pathogenicity and penetrance of putatively clinically important rare variants. Although rare
variants are harder to genotype accurately than common variants, we were able to classify as high quality 1,244 of 4,585 (27%) putatively
clinically relevant rare (MAF < 1%) variants genotyped on the UKB microarray. We defined as ‘‘clinically relevant’’ variants that were
classified as either pathogenic or likely pathogenic in ClinVar or are in genes known to cause two specific monogenic diseases: matu-
rity-onset diabetes of the young (MODY) and severe developmental disorders (DDs). We assessed the penetrance and pathogenicity
of these high-quality variants by testing their association with 401 clinically relevant traits. 27 of the variants were associated with a
UKB trait, and we were able to refine the penetrance estimate for some of the variants. For example, the HNF4A c.340C>T (p.Arg114Trp)
(GenBank: NM_175914.4) variant associated with diabetes is<10% penetrant by the time an individual is 40 years old.We also observed
associations with relevant traits for heterozygous carriers of some rare recessive conditions, e.g., heterozygous carriers of the ERCC4
c.2395C>T (p.Arg799Trp) variant that causes Xeroderma pigmentosum were more susceptible to sunburn. Finally, we refute the previ-
ous disease association of RNF135 in developmental disorders. In conclusion, this study shows that very large population-based studies
will help refine our understanding of the pathogenicity of rare genetic variants.Introduction
One of the ongoing challenges in genetic medicine is that
of variant interpretation. Many variants and genes have
been erroneously associated with disease as a result of
study design problems (including ascertainment bias and
inadequate cohort size),1–3 as well as biological phenom-
ena such as genetic heterogeneity, reduced penetrance,
variable expressivity, composite phenotypes, pleiotropy,
and epistasis.4–13 These issues have resulted in ambiguity
over how to interpret clinically ascertained variants found
in individuals with no known family history or symptoms
of the disease.14 Although there has traditionally been a
division between rare disease genetics (studied in small dis-
ease cohorts and individual high-risk families) and com-
mon disease genetics (studied in large disease cohorts
and population biobanks), in reality a continuum of cau-
sality is likely for many human disorders.15 Fortunately,
rare and common disease studies suffer from opposing
ascertainment biases. Clinical and family-based cohorts as-
certained as a result of a specific clinical presentation will
tend to overestimate the penetrance of any identified dis-
ease-causing variants.16 In contrast, population cohorts
tend to be enriched for healthy individuals (the so-called
‘‘healthy volunteer’’ selection bias) who have both the
time and ability to volunteer for a study,17,18 and they
will therefore tend to underestimate penetrance. Popula-1Institute of Biomedical and Clinical Science, University of ExeterMedical Scho
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data are therefore invaluable for establishing minimum
penetrance estimates, exploring variable expressivity, and
challenging pathogenicity assertions made in the clinical
arena.
Several studies have already started to bridge this gap by
using population data to evaluate rare disease-causing vari-
ants,19,20 refine penetrance estimates,21 and refute report-
edly pathogenic variants.22,23 These previous studies were
mostly limited to a very specific set of variants (e.g. pro-
tein-truncating variants) or one particular disease, or they
were too small to statistically test phenotypic penetrance.
With its wealth of linked phenotypic and clinical informa-
tion on 500,000 genotyped individuals, UK Biobank
(UKB)24 offers a powerful dataset inwhich to systematically
evaluate the pathogenicity, penetrance, and expressivity of
clinically important variants in the population. However,
differences in the technologies used for assaying genetic
variation can hinder these analyses. A particular concern
is the use of genotyping arrays (such as those currently
used by UKB),25 which have been designed primarily to
assay commonvariation. In contrast, rare single-nucleotide
variants (SNVs) and small insertions/deletions (indels) have
typically been detected through sequencing assays.26 A
method is therefore needed to select well-genotyped, rare
variants in UKB; this method can then be used in address-
ing biological and clinical questions.ol, Research, Innovation, Learning andDevelopment building, Royal Devon
ac.uk (M.N.W.)
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Here we describe a systematic method for evaluating the
analytical validity of rare-variant genotyping data from the
UKB arrays, investigate the relationship between data qual-
ity and minor-allele frequency (MAF), and evaluate the
association of a subset of clinically interesting, well-geno-
typed coding variants with relevant phenotypes in UKB.
We focus on ClinVar variants that have been classified as
‘‘pathogenic’’ or ‘‘likely pathogenic’’ by at least one submit-
ter,27 as well as variants in genes known to cause two spe-
cific monogenic diseases, maturity-onset diabetes of the
young (MODY [MIM: 606391]) and developmental disor-
ders (DDs), in which we have some expertise.Subjects and Methods
UKB Cohort
Between 2006 and 2010, UKB recruited more than 500,000 indi-
viduals aged 37–73 years from across the UK. Participants provided
a range of information (e.g., demographics, health status, lifestyle)
via questionnaires and interviews. Additionally, anthropometric
measurements; blood-pressure readings; and blood, urine, and
saliva samples were taken for future analysis. Genotypes for
SNVs and indels were generated from the Affymetrix Axiom
UKB array (450,000 individuals) and the UKBiLEVE array
(50,000 individuals) in 106 batches of 4,700 samples. This da-
taset underwent extensive central quality control (see Web Re-
sources).25 We limited our analysis to 379,768 QC-passed white
Europeans.Variant Prioritization
We annotated variants by using Annovar28 and calculated MAFs
by using PLINK.29 To prioritize variants of potential clinical impor-
tance, we selected those with at least one classification of pathoge-
nicity (pathogenic or likely pathogenic) in the ClinVar database;27
variants with conflicting classifications were not excluded. In
addition, irrespective of their presence in ClinVar, we selected pre-
dicted protein-truncating variants (PTVs; stopgain SNVs and
frameshift indels) and known pathogenic functional variants
(nonsynonymous SNVs and inframe indels) in genes known to
be associated with MODY30,31 and dominant DD32,33 for detailed
evaluation. These diseases and genes were selected on the basis of
our own prior experience, the availability of well-curated gene lists
that include the mode of inheritance and mechanism of action,
and the different prior probabilities associated with finding dia-
betes (a common disease) and severe DD (a rare disease) in UKB.
We excluded common variants (MAF > 1%) because these have
already been thoroughly investigated through genome-wide asso-
ciation studies,34,35 and we further refined the list of variants to
include only those where the Hardy-Weinberg equilibrium
(HWE) had a p > 0.05 and the proportion of missing genotypes
across all samples was < 0.01 (n ¼ 4,585).Assessing Analytical Validity
To assess the analytical validity of these variants, we used Evoker
Lite (see Web Resources) to generate cluster plots of intensities,
and we combined data from all the batches into one plot for
each variant. Cluster plots were manually assessed and ranked in
quality from 1–5, where 1 ¼ poor quality, no discernible separate
clusters; 2¼ poor quality, no discernible separate clusters but noisy276 The American Journal of Human Genetics 104, 275–286, Februardata; 3 ¼ unclear or uncertain; 4 ¼ good quality, clearly separable
clusters but noisy data; and 5 ¼ good quality, clear separation be-
tween clusters (Figure S1). In an initial 750-variant subset that was
independently evaluated by two scientists (Figure S2), correlation
between the two independent scorers was high (R2 ¼ 0.8), and
there was a 95% agreement in low quality (score ¼ 1 or 2) versus
high quality (score ¼ 4 or 5) variants. All remaining variants of in-
terest were evaluated by one scientist, and those with high quality
scores were checked by the second scientist. Only variants with an
average score of >4 were retained for further analysis. For all 1,244
high-quality variants, we assessed whether the rare genotype calls
were unusually distributed across the 107 genotype batches. None
of the rare genotype calls at these variants were entirely due to calls
from a single batch. Across the 1,244 variants, the highest propor-
tion of rare genotype calls in a single batch was four from a total of
13 for Affx-89007317. A plot of total allele count for each variant
versusmaximum allele count across each individual batch demon-
strated a linear association with no clear outlying variants.
Assessing Clinical Relevance
Using PLINK, we ran a phenome-wide association in 379,768
QC-passed white Europeans for all of our 1,244 high-quality rare
variants against a curated list of 401 clinically relevant traits in
UKB (Table S1)29 and those variants with a Bonferroni-corrected
p < 1310-7 (0.05/[401*1244]) were prioritized for detailed evalua-
tion. For continuous traits, we used linear regression wherein we
adjusted for age, sex (unless the trait was sex-specific), center, gen-
otyping chip, and ten ancestry principal components. For binary
traits,weused Fisher’s exact test as theprimary associationmethod.
We excluded three variants that had been reclassified in ClinVar as
benign since our variant annotation (November 2017). To assess
the potential clinical implications of high-quality rare variants,
we compared the UKB traits with the clinical presentation of the
disease for each gene and the evidence supporting the assertion
of pathogenicity of the variant by using ClinVar,27 DECIPHER,36
and OMIM.37 For high-quality rare variants in MODY genes and
PTVs in DD genes, we had no p-value cut-off for investigating dia-
betes and developmental traits (cognitive function, educational
attainment, body mass index, height, hearing, and albumin creat-
inine ratios). Conditional analysis of the most-associated regional
variant (within a 1 Mb window) from each trait led us to remove
one trait-variant association that was explained by linkage disequi-
librium with a common causal variant.Results
Variants below 0.001% Frequency Are Not Reliably
Genotyped
Across all the variants evaluated for analytical validity via
combined cluster plots (n unique ¼ 4,585; see Subjects
andMethods), we categorized 27% as high quality (average
score >4), 64% as low quality, most likely false positives
(average score <2.5), and 9% as unclear (Table 1). There
was a strong correlation between the analytical-validity
quality score and both the MAF (Table 1 and Figure 1)
and the presence of the variant in either gnomAD38 or
the 1000 genomes project.39 For low- versus high-quality
variants, a nonparametric regression analysis estimated
the area under the ROC curve to be 0.95 (95% confidence
interval (CI)¼ 0.943–0.956); the false-positive rate (FPR) aty 7, 2019
Table 1. Evaluated Variants
MAF Bin (%) FP TP Unclear Total
0–0.0005 511 0 11 522
0.0005–0.001 607 8 59 674
0.001–0.005 1,598 218 210 2,026
0.005–0.01 138 204 73 415
0.01–0.05 66 456 48 570
0.05–0.1 2 129 5 136
0.1–0.5 6 189 7 202
0.5–1 0 40 0 40
Total 2,928 1,244 413 4,585
Number of variants manually evaluated for analytical validity in different MAF
bins; quality scores are grouped into false positives (FP, score ¼ 1 or 2), unclear
scores (score ¼ 3), and true positives (TP, score ¼ 4 or 5).MAF > 0.005% was 20%, but the FPR was 60% at
MAF > 0.001%.Estimates of Minimum Effect Size for Known Pathogenic
Variants
The 1,244 high-quality, putatively pathogenic rare vari-
ants, along with their ClinVar-associated disease and the
allele frequencies in UKB and gnomAD, are shown in Table
S2. Of these variants, only 27 were associated (p< 13 10-7)
with one of the 401 traits we tested against in UKB (Table 2
and Table S3). Of these, 13 have previously been linked
with a dominant disease, although most are considered
to be only risk factors or low-penetrance variants rather
than true highly pathogenic monogenic variants. Specif-
ically, we observed well-established associations betweenThe Americavariants in HOXB1340 (MIM: 604607) and PALB241 (MIM:
610355) and prostate cancer (MIM: 176807) and breast
cancer (MIM: 114480), respectively. The effect sizes are
broadly in line with estimates from population-based
studies and consistently lower than those of family-based
studies (e.g.40,41). The HOXB13 c.251G>A (p.Gly84Glu)
variant was originally suggested to increase risk 20-fold,40
but a population-based study42 of this variant reported
an odds ratio of 3.5, 95% CI ([2.4, 5.2]), similar to the
odds ratio observed in the UKB of 4.09, 95% CI ([3.24,
5.17]). For PALB2, a similar loss-of-function variant found
at relatively high frequency in Finland had an odds ratio
of 11.3 (95% CI ([1.8, 57.81])) when family-based cases
were used, but it had an odds ratio of only 3.94, 95% CI
([1.5, 12.1]) when unselected cases were used;43 this ratio
is comparable to the estimate of 4.55, 95% CI ([3.05,
6.79]) in the UKB. The other 11 variants were causally
linked to disease, and we observed that these variants
were associated with a related trait in our population-based
cohort (Table 2). In FLG (MIM: 135940), two PTVs that
cause ichthyosis vulgaris44 (MIM: 146700) were associated
with increased odds of eczema (MIM: 603165) [odds ratios
were 1.66 (95% CI [1.40, 1.98] and 1.96 (95% CI [1.69,
2.27])], consistent with effect sizes for loss-of-function mu-
tations from previous studies.45 A TSHR (MIM: 603372)
PTV that causes nonautoimmune hyperthyroidism46
(MIM: 609152) was associated with an increased odds of
hypothyroidism (odds ratio 3.34, 95% CI [2.47, 4.51]). A
nonsynonymous LRRK2 (MIM: 609007) variant that
causes Parkinson disease (MIM: 607060) was associated
with an odds ratio of 4.76 (95% CI [3.25, 6.96]) that a per-
son would have a parent with Parkinson disease; this
estimate is consistent with studies of affected family mem-
bers.47–49 A nonsynonymous PER3 (MIM: 603427) variantFigure 1. Correlation between Minor
Allele Frequency and Analytical Validity
Quality Score
(A and B) Density plot (A) and boxplot (B)
of manual quality scores (from 1–5, see
Figure S1) of genotype data in UKB versus
minor allele frequency (MAF) for 4,585
putatively clinically important variants,
where MAF < 1%, Hardy–Weinberg
equilibrium (HWE) > 0.05, and missing-
ness < 0.01.
(C) Histogram of the number of variants at
each quality score versus presence or
absence of the variant in gnomAD (exome
data) or the 1000 Genomes Project.
Red ¼ score 1; gold ¼ score 2; green ¼
score 3; blue ¼ score 4; purple ¼ score 5.
(D) Estimation of the false-positive rate
(FPR) versus MAF for variants assayed
with the UKB genotyping arrays, calcu-
lated by the grouping of quality scores
into low (score ¼ 1 or 2) and high
(score ¼ 4 or 5) and use of the rocreg com-
mand in Stata for fitting a ROC curve.
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Table 2. Pathogenic Variants
Gene UKB ID
Position
(GRCh37) HGVS
MAF
White
British
(%)
Significantly
Associated Trait(s)
in UKB (Units)
Odds Ratio or
Beta [95% CI] p value
Linked Disease
(Mode of
Inheritance)
ACSF3 dbSNP:
rs141090143
chr16:
89220556
C>T
GenBank:
NM_174917:
c.C1672T:p.R558W
0.632 ease of sunburn
(number of episodes)
0.31 [0.20, 0.42] 4 3 1010 combined malonic
and methylmalonic
aciduria (AR)
AR dbSNP:
rs137852591
chrX:
66941751
C>G
GenBank:
NM_000044:
c.C2395G:p.Q799E
0.129 skeletal mass (SD) 0.16 [0.21,
0.11]
1 3 1010 partial androgen
insensitivity
syndrome (XLR)
height (cm) 0.85 [1.27,
0.43]
1 3 108
dbSNP:
rs1800053
chrX:
66931295
C>A
GenBank:
NM_000044:
c.C1937A:p.A646D
0.269 balding pattern
(males only)
0.13 [0.17,
0.08]
1 3 108 partial androgen
insensitivity
syndrome (XLR)
ERCC4 dbSNP:
rs121913049
chr16:
14041848
C>T
GenBank:
NM_005236:
c.C2395T:p.R799W
0.060 ease of sunburn
(number of
episodes)
0.98 [0.64, 1.33] 2 3 108 xeroderma
pigmentosum (AR)
FLG dbSNP:
rs150597413
chr1:
152277622
G>T
GenBank:
NM_002016:
c.C9740A:p.S3247X
0.369 eczema 1.66 [1.40, 1.98] 9 3 108 ichthyosis vulgaris
(AD)
dbSNP:
rs138726443
chr1:
152280023
G>A
GenBank:
NM_002016:
c.C7339T:p.R2447X
0.446 eczema 1.96 [1.69, 2.27] 5 3 1016 ichthyosis vulgaris
(AD)
GCK dbSNP:
rs104894006
chr7:
44189591
G>A
GenBank:
NM_000162:
c.C556T:p.R186X
0.001 maturity-onset
diabetes of the
young
68 [14, 325] 2 3 108 diabetes mellitus
(AD)
HBB Affx-
52141620
chr11:
5248004
G>A
GenBank:
NM_000518:
c.C118T:p.Q40X
0.005 mean corpuscular
volume (SD)
2.92 [3.26,
2.57]
6 3 1063 beta-thalassemia
(AR)*
red blood cell
distribution
width (SD)
1.87 [1.53, 2.21] 5 x 1027
HOXB13 dbSNP:
rs138213197
chr17:
46805705
C>T
GenBank:
NM_006361:
c.G251A:p.G84E
0.160 prostate cancer 4.09 [3.24, 5.17] 1 3 1023 prostate cancer
susceptibility (AD)
father with prostate
cancer
1.75 [1.47, 2.09] 4 3 109
HNF4A dbSNP:
rs137853336
chr20:
43042354
C>T
GenBank:
NM_175914:
c.340C>T:R114W
0.015 diabetes 2.9 [1.7, 5] 3 3 104 maturity-onset
diabetes of the
young (AD)
HSPA9 Affx-
80274027
chr5:
137902404
CT>-
GenBank:
NM_004134:c.882_
883del:p.T294fs
0.017 mean corpuscular
volume (SD)
0.49 [0.67,
0.32]
2 3 108 even-plus
syndrome (AR)
red blood cell
distribution
width (SD)
1.17 [0.99, 1.34] 9 3 1040
KLF1 Affx-
80299186
chr19:
12995833
->C
GenBank:
NM_006563:
c.954dupG:p.R319fs
0.017 mean corpuscular
volume (SD)
1.27 [1.45,
1.1]
9 3 1048 blood group
Lutheran inhibitor
(AD)
red blood cell
distribution
width (SD)
1.48 [1.3, 1.65] 2 3 1063
LRRK2 dbSNP:
rs34637584
chr12:
40734202
G>A
GenBank:
NM_198578:
c.G6055A:p.G2019S
0.032 parent with
Parkinson disease
4.76 [3.25, 6.96] 1 3 1011 Parkinson disease
(AD)
MYH7 Affx-
86888962
chr14:
23887458
C>T
GenBank:
NM_000257:
c.C4130T:p.T1377M
0.117 pulse rate (beats
per minute)
4.75 [5.47,
4.01]
4 3 1041 primary familial
hypertrophic
cardiomyopathy
(AD)
(Continued on next page)
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Table 2. Continued
Gene UKB ID
Position
(GRCh37) HGVS
MAF
White
British
(%)
Significantly
Associated Trait(s)
in UKB (Units)
Odds Ratio or
Beta [95% CI] p value
Linked Disease
(Mode of
Inheritance)
NPC1 dbSNP:
rs80358259
chr18:
21116700
A>G
GenBank:
NM_000271:
c.T3182C:p.I1061T
0.075 mean corpuscular
volume (SD)
0.24 [0.32,
0.15]
2 3 108 Niemann-Pick
disease (AR)
OCA2 dbSNP:
rs28934272
chr15:
28230247
C>T
GenBank:
NM_000275:
c.G1327A:p.V443I
0.834 ease of sunburn
(number of episodes)
0.49 [0.40, 0.58] 1 3 1047 oculocutaneous
albinism (AR)
dbSNP:
rs121918170
chr15:
28228529
T>C
GenBank:
NM_000275:
c.A1465G:p.N489D
0.094 ease of sunburn
(number of episodes)
0.91 [0.64, 1.18] 1 3 1014 oculocutaneous
albinism (AR)
PALB2 dbSNP:
rs180177132
chr16:
23632683
C>T
GenBank:
NM_024675:
c.G3113A:p.W1038X
0.033 breast cancer 4.55 [3.05, 6.79] 2 3 1010 familial breast
cancer (AD)
mother with breast
cancer
2.62 [1.92, 3.59] 5 3 108
PER3 dbSNP:
rs139315125
chr1:
7869960
A>G
GenBank:
NM_001289862:
c.A1250G:p.H417R
0.438 morning person 1.37 [1.27, 1.47] 2 3 1016 advanced sleep
phase syndrome
(AD)
dbSNP:
rs150812083
chr1:
7869953
C>G
GenBank:
NM_001289862:
c.C1243G:p.P415A
0.458 morning person 1.35 [1.25, 1.46] 7 3 1015
SEC23B dbSNP:
rs121918221
chr20:
18496339
G>A
GenBank:
NM_006363:
c.G325A:p.E109K
0.027 red blood cell
distribution
width (SD)
0.39 [0.25, 0.52] 3 3 108 congenital
dyserythropoietic
anemia (AR)
SLC6A19 dbSNP:
rs121434346
chr5:
1212453
G>A
GenBank:
NM_001003841:
c.G517A:p.D173N
0.442 red blood cell
distribution
width (SD)
0.15 [0.18,
0.11]
2 3 1016 neutral 1 amino
acid transport
defect (AR)
TACR3 dbSNP:
rs144292455
chr4:
104577415
C>T
GenBank:
NM_001059:
c.G824A:p.W275X
0.054 reproductive age
at menarche (yr)
0.66 [0.45, 0.87] 2 3 1010 hypogonadotropic
hypogonadism
(AR)
TMPRSS6 dbSNP:
rs137853120
chr22:
37469593
C>T
GenBank:
NM_153609:
c.G1561A:p.D521N
0.019 mean corpuscular
volume (SD)
0.67 [0.83,
0.51]
3 3 1016 microcytic anemia
(AR)
red blood cell
distribution
width (SD)
0.69 [0.53, 0.85] 5 3 1017
TSHR dbSNP:
rs121908866
chr14:
81610039
G>A
GenBank:
NM_000369:
c.G1637A:p.W546X
0.041 hypothyroid 3.34 [2.47, 4.51] 7 3 1012 hypothyroidism
(AD, AR)
autoimmune disease 2.31 [1.76, 3.04] 4 3 108
TNFRSF13B dbSNP:
rs34557412
chr17:
16852187
A>G
GenBank:
NM_012452:
c.T310C:p.C104R
0.703 mean corpuscular
volume (SD)
0.09 [0.12,
0.07]
4 3 1011 common variable
immunodeficiency
(AD, AR)
Reduced penetrance, variable expressivity, and carrier phenotypes for rare (MAF < 1%) ClinVar pathogenic variants with genome-wide significant associations in
UKB. Abbreviations are as follows: UKB ¼ UK Biobank, HGVS ¼ Human Genome Variation Society, MAF ¼ minor allele frequency, SD ¼ standard deviations,
cm ¼ centimeters, yr ¼ years, CI ¼ confidence interval, AD ¼ autosomal dominant, AR ¼ autosomal recessive, XLR ¼ X-liniked recessive.previously classified as pathogenic for advanced sleep
phase syndrome (MIM: 616882) had an odds ratio of
only 1.38 for being a morning person and advanced sleep
timing by only 8 minutes, 95% CI ([4, 13])50,51 compared
to a reported 4.2 hour shift in midpoint sleep. Height, skel-
etal weight, and male pattern baldness were negatively
associated with two nonsynonymous variants in AR
(MIM: 313700) that cause partial androgen insensitivity
syndrome.52 Finally, a nonsynonymous MYH7 variantThe America(MIM: 160760), which has been classified by a ClinGen
expert panel as pathogenic for hypertrophic cardiomyopa-
thy53 (MIM: 192600), was associated with a reduced pulse
rate of 5 (95% CI ([4, 6])) beats per minute.
Reduced Penetrance for the Common HNF4A
p.Arg114Trp MODY Mutation
We specifically investigated known pathogenic variants
and PTVs in MODY genes, where we found two raren Journal of Human Genetics 104, 275–286, February 7, 2019 279
Figure 2. Comparison of Penetrance Estimate for HNF4A
p.Arg114Trp in UK Biobank versus Previously Published Estimates
from MODY Cohort Studies
A Kaplan-Meier plot of the proportion of individuals who are dia-
betes free at various ages for 379,768 individuals from UK Biobank
(red line), 122 UK Biobank individuals who are heterozygous for
HNF4A p.Arg114Trp (green line), 26 MODY referral probands
(blue line), and 24 family members of the probands (yellow line)
from Laver et al.54variants that were high quality, definitely pathogenic, and
strongly associated with diabetes (Table 2): a very rare stop-
gain variant in GCK (MIM: 138079) (OR ¼ 68, 95% CI [14,
328], p ¼ 2 3 10-8), and a nonsynonymous variant
(p.Arg114Trp) in HNF4A (MIM: 600281) (OR ¼ 2.9, 95%
CI [1.7, 5.0], p ¼ 3 3 10-4). Both were associated with dia-
betes in UKB, in line with previous findings.54–56 However,
the penetrance of the HNF4A variant was previously esti-
mated on the basis of a large MODY diabetes cohort to
be up to 75% at age 40 years,54 although we estimate the
minimum penetrance to be <10% from UKB (Figure 2).
This has important implications for the attributable risk
associated with the variant in different cohorts and for
the interpretation of genetic test results: if the p.Arg114Trp
variant was found in an affected individual after clinical
testing, it might still be the primary cause of that person’s
diabetes, although incidental discovery of the variant in an
unaffected individual would not be predictive.
Related Mild Heterozygous Phenotypes in Autosomal-
Recessive Disorders
Of our 27 high-quality, rare putatively pathogenic variants
associated with a trait in UKB, 16 have previously been
linked with a recessive disease (Table 2). We observed asso-
ciations with milder or related traits in the heterozygous
carriers of these monogenic recessive diseases in our popu-
lation cohort. A nonsynonymous ERCC4 (MIM: 133520)
variant that causes recessive xeroderma pigmentosum57
and two nonsynonymous OCA2 (MIM: 611409) variants
that cause oculocutaneous albinism58,59 (MIM: 203200)
were associated with ease of sunburn. A stopgain TACR3
(MIM: 162332) variant, which causes recessive hypogona-
dotropic hypogonadism60,61 (MIM: 614840), was associ-
ated with an 8 month increase in age at which a girl280 The American Journal of Human Genetics 104, 275–286, Februarexperiences menarche. In addition, variants in six genes
known to be associated with different recessive blood-
related disorders were also associated with decreased
mean corpuscular volume and/or increased red blood cell
distribution width (such genes included HBB [MIM:
141900], variants in which cause b-thalassemia (MIM:
612985), but the carrier state is already known to cause
the much milder b-thalassemia minor62).
Benign Protein-Truncating Variants in Monogenic
Genes
We focused our clinical analysis of variants in DD genes on
just PTVs, of which six (including two variants in one
gene) were of high quality and were in genes that are re-
ported to cause disease via a haploinsufficiency mecha-
nism (Table 3). None of these variants were associated
with developmentally relevant traits in UKB (p > 0.1), sug-
gesting they are all benign. For three variants, the location
of the variant in the gene is notably different from that of
known pathogenic variants. GNAS (MIM: 139320) is the
only one of the five genes with a high probability of being
loss-of-function intolerant (pLI)38 on the basis of the fre-
quency of loss-of-function variants in the Exome Aggrega-
tion Consortium (ExAC) browser.38 The stop-gain variant
in GNAS is present in the highly variable first exon of the
gene and is likely to result in nonsense-mediated RNA
decay; in contrast, pathogenic GNAS variants that cause
Albright hereditary osteodystrophy (MIM: 103580) are
located in later, highly constrained exons.63 Similarly,
the stop-gain variant in TGIF1 (MIM: 602630) is located
in the first exon, where multiple PTVs in gnomAD38 are
also located, but TGIF1 pathogenic variants causing holo-
prosencephaly are located in the final exons, where they
affect DNA binding affinity.64 Finally, a frameshift deletion
in HIST1H1E (MIM: 142220) is located near the start of the
single exon of this gene; however, pathogenic HIST1H1E
frameshift deletions that cause child overgrowth and intel-
lectual disability are located near the end of the exon,
where they result in a truncated histone protein with lower
net charge that is less effective at binding DNA.65 Hence,
we believe that these three rare PTVs are benign because
of their locations, despite the fact that they occur in genes
that cause dominant DD via haploinsufficiency.
Refuting Previous Disease Associations
For the other three DD variants, our findings are not
consistent with the genes’ causing a dominant DD via hap-
loinsufficiency. First, there was no association between a
frameshift variant in the middle of COL4A3 (MIM:
120070)—where pathogenic variants are thought to
cause a rare dominant form of Alport syndrome (MIM:
104200) (as well as benign familial hematuria [MIM:
141200])66,67—and albumin creatinine ratios, hearing, or
any of the development traits in UKB. Similarly, there
was no association between either stop-gain or frameshift
variants in RNF135 (MIM: 611358) —where haploinsuffi-
ciency is thought to cause macrocephaly, macrosomia,y 7, 2019
Table 3. Benign Variants
Gene UKB ID Position (GRCh37) HGVS MAF (%) Biobank Trait Beta [95% CI] p Value
Linked Monogenic
Disease
COL4A3 Affx-80270894 chr2: 228148945
G>GAGTAAAGGGCC
GenBank:
NM_000091:
c.2766_2776del:
p.G922fs
0.01813 education years 0.007 [0.17, 0.156] 0.93 DD (Alport syndrome,
fluid intelligence 0.085 [0.3, 0.133] 0.45 autosomal dominant)
BMI 0.096 [0.07, 0.259] 0.25
height 0.097 [0.26, 0.066] 0.24
albumin creatine
ratio
0.941 [0.44, 2.015] 0.88
hearing left 0.13 [0.41, 0.144] 0.35
hearing right 0.076 [0.2, 0.35] 0.59
GNAS dbSNP:
rs200910410
chr20: 57428858 T>C GenBank:
NM_080425:
c.C538T:p.Q180X
0.03063 education years 0.053 [0.18, 0.072] 0.41 DD (Albright hereditary
fluid intelligence 0.062 [0.12, 0.239] 0.49 osteodystrophy)
BMI 0.048 [0.08, 0.174] 0.46
height 0.105 [0.23, 0.021] 0.10
HIST1H1E Affx-89024826 chr6: 26156672 T>TC GenBank:
NM_005321:
c.55delC:p.P19fs
0.02438 education years 0.098 [0.05, 0.24] 0.18 DD (Childhood
fluid intelligence 0.1 [0.1, 0.302] 0.33 overgrowth)
BMI 0.014 [0.16, 0.129] 0.85
height 0.059 [0.08, 0.202] 0.42
RNF135 dbSNP:
rs121918161
chr17: 29324307 T>C GenBank:
NM_032322:
c.C727T:p.Q243X
0.00215 education years 0.341 [0.11, 0.79] 0.14 DD (macrocephaly,
fluid intelligence 0.16 [0.41, 0.726] 0.58 macrosomia,
BMI 0.177 [0.27, 0.626] 0.44 facial dysmorphism
height 0.082 [0.37, 0.532] 0.72 syndrome)
Affx-80285705 chr17: 29325809
G>GC
0.05265 education years 0.02 [0.08, 0.115] 0.68
fluid intelligence 0.097 [0.23, 0.032] 0.14
BMI 0.017 [0.08, 0.113] 0.72
height 0.03 [0.07, 0.125] 0.54
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282 The American Journal of Human Genetics 104, 275–286, Februarand facial dysmorphism syndrome68 (MIM:614192)—with
any development traits in UKB. In both cases, given the
high-quality genotyping of these variants in UKB and a
lack of association with any clinically relevant traits,
together with a pLI of zero for both genes, the age of the
original publications, and the lack of enrichment of
de novo mutations within the DDD study,33 we suggest
that haploinsufficiency in these genes is not a cause of a
severe DD.Discussion
Previous studies have been unable to analyze rare variants
in sufficiently large population-based studies to establish
pathogenicity and lower bounds for penetrance. Large
population cohorts such as UKB provide an opportunity
to investigate the relationship between genes and disease.
However, the absence of genome-wide sequencing data
has thus far minimized the impact of UKB in the rare dis-
ease community. We have established a method, using
combined intensity plots for individual variants across all
genotyping batches, for evaluating the analytical validity
of rare variants genotyped by microarray. Although we
initially tried to examine variant cluster plots for each
batch separately, as recommended by UKB, this proved
impossible because of the rarity of most clinically impor-
tant variants. MAF was an extremely good predictor of
the likelihood that a variant would be genotyped well by
the UKB arrays (Figure 1). At MAF > 0.005% (50 hetero-
zygous individuals out of 500,000 in UKB) the FPR was
7%, and most variants were well genotyped, but the
FPR was 60% at MAF > 0.001% (10 heterozygous indi-
viduals), and we classified all variants at MAF < 0.0005%
(5 heterozygous individuals) as being low quality. This
has important implications for epidemiological research
carried out uncritically with these data. Although many
rare variants in UKB are well-genotyped with the arrays,
the rarer the variant, the more likely it is to be poor quality
and therefore yield false associations.
A limitation of our work is that we did not attempt to
confirm the variants by using an independent assay. How-
ever, most researchers using data from UKB will be
similarly unable to attempt independent variant confirma-
tions, and thus a method for evaluating the genotyping
quality of rare variants directly from the data has wide-
spread utility. The validity of our method is supported by
our ability to replicate numerous previous findings of
well-known, clinically important variants classified as
pathogenic in ClinVar (Table 2 and Table S3, plus addi-
tional well-established associations for variants where
MAF > 1%). In addition, our analyses of likely pathogenic
variants in two disease subtypes (MODY and DD) were in-
dependent of any potential biases or misclassification
errors associated with ClinVar, and the findings were
consistent with our prior expectations. We expected
there to be a small number of individuals in UKB withy 7, 2019
monogenic subtypes of diabetes, and we found two patho-
genic variants that were associated with appropriate traits
in UKB (Table 2); we were thus able to lower the previous
penetrance estimate for a pathogenic variant in HNF4A
(Figure 2). In contrast, we did not expect there to be any in-
stances of severe DD, in light of the rarity of the condition,
the relatively senior age of the UKB population, and the
inherent challenges of obtaining consent from individuals
with severe DD to be added to population biobanks.69 We
therefore believe that the PTVs identified in dominant DD
genes in UKB are benign (Table 3) and are confident in
refuting previous associations between haploinsufficiency
in RNF135 and COL4A3 and dominant DD (note that
this refutation has no bearing on the asserted relationship
between the latter and either recessive DD or alternative
mechanisms of disease).
In this study, we have shown that population genetic
data can be used for estimating lower bounds for the
effect size and penetrance of pathogenic, disease-causing
variants and refined our understanding of the links
between rare variants (MAF<1%) andmonogenic diseases.
Performing a similar analysis on very rare variants
(MAF <0.001%) will require large-scale sequencing data
rather than genotyping arrays. Although population-based
studies will be biased in the opposite direction from clin-
ical studies, i.e. towards healthy individuals, they are none-
theless crucial for informingminimum and age-dependent
penetrance estimates, interpreting incidental or secondary
findings from clinical testing, and informing direct-to-con-
sumer genetic testing. At this point, we are left with some
fundamental conceptual questions about the nature of
‘‘monogenic’’ disease. When should variants exhibiting
reduced penetrance—a term frequently used in the diag-
nosis of rare genetic disease—be called risk or susceptibility
factors, terms generally used in the study of common
disease? When should a gene-disease relationship be
termed variable expressivity rather than normal variation?
Should ‘‘pathogenic’’ be reserved only for highly penetrant
variants that cause a tightly defined disease entity, or can
it apply to any variant associated, however weakly,
with a clinically relevant phenotype? As genome-wide
sequencing becomes widely used in routine clinical prac-
tice, research cohorts, and direct-to-consumer testing, un-
derstanding this spectrum will become both increasingly
important and tractable.Supplemental Data
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be found with this article online at https://doi.org/10.1016/j.ajhg.
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